

SUPPORTING INFORMATION





Synthesis of 6-methyl-3,4-dihydropyrazinones using a Ugi 4-CR/allenamide cycloisomerization protocol



Estefanía Icelo-Ávila,^a Yoarhy A. Amador-Sánchez,^a Luis A. Polindara-García,^{*a} Luis D. Miranda^{*a}





Instituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510, Ciudad de México, México.





| | |
|--|-----|
| Ugi adducts spectra 11a-x | S2 |
| Dihydropyrazinone spectra 13a-x | S27 |
| Tricyclic pyrazinones spectra 14q-x | S55 |
| X-Ray crystallographic data | S63 |





Ugi Adducts spectra



***N*-(2,6-dimethylphenyl)-2-(*N*-(prop-2-yn-1-yl)acetamido)pentanamide (11a)**300 MHz, CDCl₃75 MHz, CDCl₃



***N*-(2,6-dimethylphenyl)-3-methyl-2-(*N*-(prop-2-yn-1-yl)acetamido)butanamide (11b).**

***N*-(2,6-dimethylphenyl)-2-(*N*-(prop-2-yn-1-yl)acetamido)hexanamide (11c)**300 MHz, CDCl₃75 MHz, CDCl₃


***N*-(2,6-dimethylphenyl)-2-(*N*-(prop-2-yn-1-yl)acetamido)butanamide (11d)**300 MHz, CDCl₃75 MHz, CDCl₃

***N*-(2,6-dimethylphenyl)-2-(*N*-(prop-2-yn-1-yl)acetamido)acetamide (11e)**300 MHz, CDCl₃75 MHz, CDCl₃



***N*-(2,6-dimethylphenyl)-4-phenyl-2-(*N*-(prop-2-yn-1-yl)acetamido)butanamide (11f)**

***N*-(1-((2,6-dimethylphenyl)amino)-1-oxohexan-2-yl)-*N*-(prop-2-yn-1-yl)benzamide (11g)**


***N*-(1-((2,6-dimethylphenyl)amino)-3-methyl-1-oxobutan-2-yl)-*N*-(prop-2-yn-1-yl)benzamide (11h)**




300 MHz, CDCl₃





75 MHz, CDCl₃




***N*-((2,6-dimethylphenyl)amino)-1-oxobutan-2-yl)-*N*-(prop-2-yn-1-yl)benzamide
(11i)**









300 MHz, CDCl₃









75 MHz, CDCl₃











***N*-cyclohexyl-2-(*N*-(prop-2-yn-1-yl)acetamido)butanamide (11j)**

***N*-cyclohexyl-2-(*N*-(prop-2-yn-1-yl)acetamido)pentanamide (11k).**300 MHz, CDCl₃75 MHz, CDCl₃


N-cyclohexyl-3-methyl-2-(N-(prop-2-yn-1-yl)acetamido)butanamide (11l)

***N*-cyclohexyl-2-(*N*-(prop-2-yn-1-yl)acetamido)hexanamide (11m)**300 MHz, CDCl₃75 MHz, CDCl₃



***N*-(1-(cyclohexylamino)-1-oxobutan-2-yl)-*N*-(prop-2-yn-1-yl)benzamide (11n)**300 MHz, CDCl₃75 MHz, CDCl₃

***N*-(1-(cyclohexylamino)-1-oxopentan-2-yl)-*N*-(prop-2-yn-1-yl)benzamide (11o)**300 MHz, CDCl₃75 MHz, CDCl₃


***N*-(1-((2,6-dimethylphenyl)amino)-1-oxohexan-2-yl)-2-iodo-*N*-(prop-2-yn-1-yl)benzamide (11p)**









300 MHz, CDCl₃











75 MHz, CDCl₃











***N*-1-((2,6-dimethylphenyl)amino)-1-oxobutan-2-yl)-2-iodo-*N*-(prop-2-yn-1-yl)-benzamide (11q)**





***N*-(1-((2,6-dimethylphenyl)amino)-1-oxopropan-2-yl)-2-iodo-*N*-(prop-2-yn-1-yl)benzamide (11r)**400 MHz, CDCl₃100 MHz, CDCl₃



***N*-(1-(cyclohexylamino)-1-oxohexan-2-yl)-2-iodo-*N*-(prop-2-yn-1-yl)benzamide (11s)**300 MHz, CDCl₃75 MHz, CDCl₃

***N*-(1-(cyclohexylamino)-1-oxopropan-2-yl)-2-iodo-*N*-(prop-2-yn-1-yl)benzamide (11t)**300 MHz, CDCl₃75 MHz, CDCl₃





***N*-(1-(*tert*-butylamino)-1-oxobutan-2-yl)-2-iodo-*N*-(prop-2-yn-1-yl)benzamide (11u)**300 MHz, CDCl₃75 MHz, CDCl₃

***N*-(1-(benzylamino)-3-methyl-1-oxobutan-2-yl)-2-iodo-*N*-(prop-2-yn-1-yl)benzamide (11v)**300 MHz, CDCl₃75 MHz, CDCl₃





**2-iodo-N-(1-(naphthalen-2-ylamino)-1-oxobutan-2-yl)-N-(prop-2-yn-1-yl)benzamide
(11w)**300 MHz, CDCl₃75 MHz, CDCl₃





2-(2-(2-iodophenyl)-N-(prop-2-yn-1-yl)acetamido)-N-(4-methoxyphenyl)butanamide (11x)

2-(4-chlorophenyl)-N-cyclohexyl-2-(N-(prop-2-yn-1-yl)acetamido)acetamide (11y)



300 MHz, CDCl₃75 MHz, CDCl₃





Dihydropyrazinone spectra

4-Acetyl-1-(2,6-dimethylphenyl)-6-methyl-3-propyl-3,4-dihydropyrazin-2(1H)-one
(13a)300 MHz, CDCl₃75 MHz, CDCl₃





4-Acetyl-1-(2,6-dimethylphenyl)-3-isopropyl-6-methyl-3,4-dihydropyrazin-2(1H)-one (13b)300 MHz, CDCl₃75 MHz, CDCl₃





4-Acetyl-3-butyl-1-(2,6-dimethylphenyl)-6-methyl-3,4-dihydropyrazin-2(1H)-one (13c)








4-Acetyl-1-(2,6-dimethylphenyl)-3-ethyl-6-methyl-3,4-dihydropyrazin-2(1H)-one (13d)300 MHz, CDCl₃75MHz, CDCl₃

4-Acetyl-1-(2,6-dimethylphenyl)-6-methyl-3,4-dihydropyrazin-2(1H)-one (13e).



300 MHz, CDCl₃75 MHz, CDCl₃

4-Acetyl-1-(2,6-dimethylphenyl)-6-methyl-3-phenethyl-3,4-dihydropyrazin-2(1H)-one (13f)


(Variable-temperature ^1H NMR studies for compound 13f)300 MHz, toluene- d_6 , 30 $^\circ\text{C}$ 300 MHz, toluene- d_6 , 60 $^\circ\text{C}$ 




300 MHz, toluene- d_6 , 70 °C








300 MHz, toluene- d_6 , 80 °C













300 MHz, toluene- d_6 , 90 °C











**4-Benzoyl-3-butyl-1-(2,6-dimethylphenyl)-6-methyl-3,4-dihydropyrazin-2(1H)-one
(13g)**300 MHz, CDCl₃75 MHz, CDCl₃

4-Benzoyl-1-(2,6-dimethylphenyl)-3-isopropyl-6-methyl-3,4-dihydropyrazin-2(1H)-one (13h)300 MHz, CDCl₃75 MHz, CDCl₃





4-benzoyl-1-(2,6-dimethylphenyl)-3-ethyl-6-methyl-3,4-dihydropyrazin-2(1H)-one (13i).300 MHz, CDCl₃75 MHz, CDCl₃

4-Acetyl-1-cyclohexyl-3-ethyl-6-methyl-3,4-dihydropyrazin-2(1H)-one (13j)





300 Mhz, CDCl₃75 MHz, CDCl₃

4-Acetyl-1-cyclohexyl-6-methyl-3-propyl-3,4-dihydropyrazin-2(1H)-one (13k)300 MHz, CDCl₃75 MHz, CDCl₃





4-Acetyl-1-cyclohexyl-3-isopropyl-6-methyl-3,4-dihydropyrazin-2(1H)-one (131)

300 MHz, CDCl₃75 MHz, CDCl₃





4-Acetyl-3-butyl-1-cyclohexyl-6-methyl-3,4-dihydropyrazin-2(1H)-one (13m)





300 MHz, CDCl₃75 MHz, CDCl₃





4-Benzoyl-1-cyclohexyl-3-ethyl-6-methyl-3,4-dihydropyrazin-2(1H)-one (13n)





300 MHz, CDCl₃75 MHz, CDCl₃





4-Benzoyl-1-cyclohexyl-6-methyl-3-propyl-3,4-dihydropyrazin-2(1H)-one (13o)





300 MHz, CDCl₃75 MHz, CDCl₃





3-Butyl-1-(2,6-dimethylphenyl)-4-(2-iodobenzoyl)-6-methyl-3,4-dihydropyrazin-2(1H)-one (13p)300 MHz, CDCl₃75 MHz, CDCl₃





1-(2,6-Dimethylphenyl)-3-ethyl-4-(2-iodobenzoyl)-6-methyl-3,4-dihydropyrazin-2(1H)-one (13q)400 MHz, CDCl₃100 MHz, CDCl₃





1-(2,6-Dimethylphenyl)-4-(2-iodobenzoyl)-3,6-dimethyl-3,4-dihydropyrazin-2(1H)-one (13r).300 MHz, CDCl₃75 MHz, CDCl₃



3-Butyl-1-cyclohexyl-4-(2-iodobenzoyl)-6-methyl-3,4-dihydropyrazin-2(1H)-one (13s)300 MHz, CDCl₃75 MHz, CDCl₃





1-Cyclohexyl-4-(2-iodobenzoyl)-3,6-dimethyl-3,4-dihydropyrazin-2(1H)-one (13t)400 MHz, CDCl₃100 MHz, CDCl₃

1-(*Tert*-butyl)-3-ethyl-4-(2-iodobenzoyl)-6-methyl-3,4-dihydropyrazin-2(1*H*)-one (13u)300 MHz, CDCl₃75 MHz, CDCl₃



1-Benzyl-4-(2-iodobenzoyl)-3-isopropyl-6-methyl-3,4-dihydropyrazin-2(1H)-one (13v)300 MHz, CDCl₃75 MHz, CDCl₃





3-Ethyl-4-(2-iodobenzoyl)-6-methyl-1-(naphthalen-2-yl)-3,4-dihydropyrazin-2(1H)-one (13w)300 MHz, CDCl₃75 MHz, CDCl₃





3-Ethyl-4-(2-(2-iodophenyl)acetyl)-1-(4-methoxyphenyl)-6-methyl-3,4-dihydropyrazin-2(1H)-one (13x)





**1-Acetyl-2-(4-chlorophenyl)-*N*-cyclohexyl-2,5-dihydro-1*H*-pyrrole-2-carboxamide
(12y)**300 MHz, CDCl₃75 MHz, CDCl₃





Tricyclic pyrazinone spectra



2-(2,6-Dimethylphenyl)-4-ethyl-1-methylpyrazino[2,1-*a*]isoindole-3,6(2*H*,4*H*)-dione
(14q)





2-(2,6-Dimethylphenyl)-1,4-dimethylpyrazino[2,1-*a*]isoindole-3,6(2*H*,4*H*)-dione (14r)300 MHz, CDCl₃75 MHz, CDCl₃



4-Butyl-2-cyclohexyl-1-methylpyrazino[2,1-*a*]isoindole-3,6(2*H*,4*H*)-dione (14s)300 MHz, CDCl₃75 MHz, CDCl₃

2-Cyclohexyl-1,4-dimethylpyrazino[2,1-*a*]isoindole-3,6(2*H*,4*H*)-dione (14t)400 MHz, CDCl₃100 MHz, CDCl₃

2-(*Tert*-butyl)-4-ethyl-1-methylpyrazino[2,1-*a*]isoindole-3,6(2*H*,4*H*)-dione (14u)300 MHz, CDCl₃75 MHz, CDCl₃

2-Benzyl-4-isopropyl-1-methylpyrazino[2,1-*a*]isoindole-3,6(2*H*,4*H*)-dione (14v)

4-Ethyl-1-methyl-2-(naphthalen-2-yl)pyrazino[2,1-*a*]isoindole-3,6(2*H*,4*H*)-dione (14w)300 MHz, CDCl₃75 MHz, CDCl₃

4-Ethyl-2-(4-methoxyphenyl)-1-methyl-2H-pyrazino[2,1-a]isoquinoline-3,6(4H,7H)-dione (14x)

X-Ray Crystallographic Data




Figure 1. Molecular structure for compound **11a**, thermal ellipsoids are drawn at 30 % probability for all atoms except than hydrogen.

Table 1. Crystal data and structure refinement for **11a**. Identification code 376MGL14 (Solved by: R. A. Toscano)

| | | |
|----------------------|---|----------------|
| Compound | 11a | |
| Empirical formula | C ₁₈ H ₂₄ N ₂ O ₂ | |
| Formula weight | 300.39 | |
| Temperature | 298(2) K | |
| Wavelength | 0.71073 Å | |
| Crystal system | Orthorhombic | |
| Space group | <i>P</i> b c a | |
| Unit cell dimensions | <i>a</i> = 9.344(3) Å | α = 90° |
| | <i>b</i> = 22.993(7) Å | β = 90° |
| | <i>c</i> = 16.649(5) Å | γ = 90° |
| Volume | 3576.9(19) Å ³ | |
| <i>Z</i> | 8 | |
| Density (calculated) | 1.116 Mg/m ³ | |

| | |
|--|--|
| Absorption coefficient | 0.073 mm ⁻¹ |
| $F(000)$ | 1296 |
| Crystal size / colour / shape | 0.380 x 0.132 x 0.058 mm / colourless / prism |
| Theta range for data collection | 2.153 to 27.610° |
| Index ranges | -11 ≤ h ≤ 12, -29 ≤ k ≤ 29, -21 ≤ l ≤ 14 |
| Reflections collected | 22418 |
| Independent reflections | 4111 [$R(\text{int}) = 0.1461$] |
| Completeness to theta = 25.242° | 99.9 % |
| Measurement device | Bruker Smart Apex CCD diffractometer 01-670-01 |
| Absorption correction | Semi-empirical from equivalents |
| Max. and min. transmission | 0.9958 and 0.9728 |
| Refinement method | Full-matrix least-squares on F^2 |
| Data / restraints / parameters | 4111 / 0 / 207 |
| Goodness-of-fit on F^2 | 1.001 |
| Final R indices [$I > 2\sigma(I)$] | $R1 = 0.0763$, $wR2 = 0.1767$ |
| R indices (all data) | $R1 = 0.1588$, $wR2 = 0.2355$ |
| Extinction coefficient | 0.0077(16) |
| Largest diff. peak and hole | 0.302 and -0.226 e.Å ⁻³ |




Figure 2. Molecular structure for compound **13a**, thermal ellipsoids are drawn at 30 % probability for all atoms except than hydrogen.

Table 2. Crystal data and structure refinement for **13a**. Identification code 361MGL14 (Solved by: R. A. Toscano)

| | |
|------------------------|--|
| Compound | 13a |
| Empirical formula | C ₁₈ H ₂₄ N ₂ O ₂ |
| Formula weight | 300.39 |
| Temperature | 298(2) K |
| Wavelength | 0.71073 Å |
| Crystal system | Monoclinic |
| Space group | <i>P</i> 2 ₁ /n |
| Unit cell dimensions | <i>a</i> = 7.2997(3) Å α = 90° <i>b</i> = 8.7192(7) Å β = 90° <i>c</i> = 27.1071(5) Å γ = 90° |
| Volume | 1710.00(12) Å ³ |
| <i>Z</i> | 4 |
| Density (calculated) | 1.167 Mg/m ³ |
| Absorption coefficient | 0.076 mm ⁻¹ |

| | |
|--|--|
| $F(000)$ | 648 |
| Crystal size / colour / shape | 0.491 x 0.305 x 0.279 mm / colourless / prism |
| Theta range for data collection | 2.456 to 27.518° |
| Index ranges | $-9 \leq h \leq 9$, $-11 \leq k \leq 11$, $-34 \leq l \leq 35$ |
| Reflections collected | 16910 |
| Independent reflections | 3930 [$R(\text{int}) = 0.0343$] |
| Completeness to theta = 25.242° | 99.8 % |
| Measurement device | Bruker Smart Apex CCD diffractometer 01-670-01 |
| Absorption correction | Semi-empirical from equivalents |
| Max. and min. transmission | 0.9790 and 0.9635 |
| Refinement method | Full-matrix least-squares on F^2 |
| Data / restraints / parameters | 3930 / 0 / 204 |
| Goodness-of-fit on F^2 | 1.035 |
| Final R indices [$I > 2\sigma(I)$] | $R1 = 0.0472$, $wR2 = 0.1161$ |
| R indices (all data) | $R1 = 0.0708$, $wR2 = 0.1310$ |
| Largest diff. peak and hole | 0.201 and -0.180 e.Å ⁻³ |




Figure 3. Molecular structure for compound **14r**, thermal ellipsoids are drawn at 30 % probability for all atoms except than hydrogen.

Table 3. Crystal data and structure refinement for **14r**. Identification code 364MGL15 (Solved by: R. A. Toscano)

| | |
|------------------------|---|
| Compound | 14r |
| Empirical formula | C ₂₁ H ₂₀ N ₂ O ₂ |
| Formula weight | 332.39 |
| Temperature | 298(2) K |
| Wavelength | 0.71073 Å |
| Crystal system | Monoclinic |
| Space group | <i>P</i> 2 ₁ /n |
| Unit cell dimensions | <i>a</i> = 8.2348(7) Å α = 90° <i>b</i> = 26.914(2) Å β = 90° <i>c</i> = 8.2642(3) Å γ = 90° |
| Volume | 1733.3(3) Å ³ |
| Z | 4 |
| Density (calculated) | 1.274 Mg/m ³ |
| Absorption coefficient | 0.083 mm ⁻¹ |
| <i>F</i> (000) | 704 |

| | |
|--|--|
| Crystal size | 0.360 x 0.280 x 0.200 mm |
| Theta range for data collection | 2.712 to 25.319° |
| Index ranges | $-9 \leq h \leq 9$, $-32 \leq k \leq 31$, $-9 \leq l \leq 9$ |
| Reflections collected | 19869 |
| Independent reflections | 3138 [$R(\text{int}) = 0.0826$] |
| Completeness to theta = 25.242° | 100.0 % |
| Measurement device | Bruker Smart Apex CCD diffractometer 01-670-01 |
| Refinement method | Full-matrix least-squares on F^2 |
| Data / restraints / parameters | 3138 / 0 / 231 |
| Goodness-of-fit on F^2 | 1.070 |
| Final R indices [$I > 2\sigma(I)$] | $R1 = 0.0532$, $wR2 = 0.1406$ |
| R indices (all data) | $R1 = 0.0664$, $wR2 = 0.1508$ |
| Extinction coefficient | 0.018(3) |
| Largest diff. peak and hole | 0.250 and -0.209 e.Å ⁻³ |




Figure 4. Molecular structure for compound **14v**, thermal ellipsoids are drawn at 30 % probability for all atoms except than hydrogen.

Table 4. Crystal data and structure refinement for **14v**. Identification code 364MGL15
(Solved by: R. A. Toscano)

| | | |
|------------------------|---|---------------------|
| Compound | 14v | |
| Empirical formula | C ₂₂ H ₂₂ N ₂ O ₂ | |
| Formula weight | 346.41 | |
| Temperature | 296(2) K | |
| Wavelength | 0.71073 Å | |
| Crystal system | Monoclinic | |
| Space group | <i>P</i> 2 ₁ /n | |
| Unit cell dimensions | <i>a</i> = 14.0741(7) Å | $\alpha = 90^\circ$ |
| | <i>b</i> = 8.4735(2) Å | $\beta = 90^\circ$ |
| | <i>c</i> = 16.5267(3) Å | $\gamma = 90^\circ$ |
| Volume | 1785.99(11) Å ³ | |
| <i>Z</i> | 4 | |
| Density (calculated) | 1.288 Mg/m ³ | |
| Absorption coefficient | 0.083 mm ⁻¹ | |

| | |
|--|---|
| $F(000)$ | 736 |
| Crystal size | 0.256 x 0.176 x 0.087 mm |
| Theta range for data collection | 2.497 to 25.390° |
| Index ranges | $-16 \leq h \leq 16$, $-10 \leq k \leq 8$, $-19 \leq l \leq 19$ |
| Reflections collected | 13978 |
| Independent reflections | 3275 [$R(\text{int}) = 0.0317$] |
| Completeness to theta = 25.242° | 99.6 % |
| Measurement device | Bruker Smart Apex CCD diffractometer 01-670-01 |
| Refinement method | Full-matrix least-squares on F^2 |
| Data / restraints / parameters | 3275 / 0 / 238 |
| Goodness-of-fit on F^2 | 1.040 |
| Final R indices [$I > 2\sigma(I)$] | $R1 = 0.0409$, $wR2 = 0.1019$ |
| R indices (all data) | $R1 = 0.0499$, $wR2 = 0.1081$ |
| Largest diff. peak and hole | 0.139 and -0.151 e.Å ⁻³ |